Home › Cases › Major Haemorrhage on Anticoagulation
Major Haemorrhage on Anticoagulation
Major Haemorrhage on Anticoagulation
6 questions
Question 1 · Identify the Anticoagulant
Correct answer: Identify whether he is on warfarin, a DOAC (dabigatran, rivaroxaban, apixaban, edoxaban), or LMWH — each has a different reversal strategy
Why
Identifying the specific anticoagulant is critical because reversal strategies differ entirely. Key anticoagulants to consider: Warfarin (vitamin K antagonist, monitored by INR, reversed by vitamin K + 4-factor PCC or FFP). DOACs: Dabigatran (direct thrombin inhibitor, reversed by idarucizumab); Rivaroxaban/apixaban (factor Xa inhibitors: andexanet alfa or 4-factor PCC). Edoxaban: urgent haematology advice; no licensed andexanet regimen. LMWH (e.g. enoxaparin, dalteparin, tinzaparin — reversed by protamine sulphate). Check the patient's medication bag, GP records, pharmacy summary, and the Summary Care Record (SCR). Helpful clues: INR monitoring = warfarin; blue DOAC alert card; renal function (dabigatran renally cleared; contraindicated in CKD4–5). Activate the major haemorrhage protocol immediately.
Key point
Always identify the specific anticoagulant before reversing — warfarin (INR + 4-PCC), dabigatran (idarucizumab), rivaroxaban/apixaban (andexanet alfa or 4-PCC), and LMWH (protamine sulphate) each require different reversal.
Question 2 · Warfarin Reversal
Correct answer: Give vitamin K 5–10mg IV immediately plus 4-factor prothrombin complex concentrate (4-PCC, e.g. Beriplex) dosed by INR and body weight
Why
For life-threatening haemorrhage on warfarin, the dual strategy is: (1) Vitamin K 5–10mg IV (slow infusion, not bolus — anaphylaxis risk with rapid IV) to provide sustained reversal over 6–12 hours. (2) 4-factor prothrombin complex concentrate (4-PCC) — e.g. Beriplex or Octaplex — for immediate reversal. 4-PCC contains factors II, VII, IX, X and proteins C and S. Dosing is weight and INR-based (typically 25–50 units/kg — check local protocol and SPC). 4-PCC is superior to FFP: faster reversal, smaller volume (important in patients at risk of fluid overload), and no requirement for blood group matching. FFP (15 ml/kg) can be used if 4-PCC is unavailable. Recheck INR 15–30 minutes post-PCC.
Key point
Warfarin reversal in major haemorrhage: vitamin K 5–10mg IV + 4-factor PCC (Beriplex) dosed by INR and weight — 4-PCC is faster and lower-volume than FFP.
Question 3 · DOAC Reversal
Correct answer: Idarucizumab (Praxbind) 5g IV as two 2.5g doses
Why
Idarucizumab (Praxbind) is the specific reversal agent for dabigatran. It is a humanised monoclonal antibody fragment that binds dabigatran with 350-times greater affinity than thrombin, completely neutralising its anticoagulant effect within minutes. The dose is 5g IV given as two separate 2.5g doses (each vial = 2.5g/50mL), administered consecutively. Licensed for: life-threatening or uncontrolled haemorrhage, emergency surgery/urgent procedures. Andexanet alfa (Ondexxya) is licensed for reversal of apixaban or rivaroxaban in life-threatening/uncontrolled bleeding; edoxaban has no licensed andexanet regimen — it is a modified recombinant factor Xa decoy that sequesters Xa inhibitors. For rivaroxaban/apixaban, 4-PCC (25–50 units/kg) is also widely used as an alternative when andexanet alfa is unavailable. Standard coagulation tests (PT, APTT) are unreliable for monitoring DOAC levels — send anti-Xa levels for Xa inhibitors and thrombin time (TT) or ecarin clotting time for dabigatran.
Key point
Dabigatran is reversed with idarucizumab (Praxbind) 5g IV; rivaroxaban/apixaban are reversed with andexanet alfa (Ondexxya) or 4-PCC — know which agent matches which DOAC.
Question 4 · LMWH Reversal
Correct answer: Give protamine sulphate 40mg IV over 10 minutes (1mg per 1mg enoxaparin; maximum 50mg per dose)
Why
Protamine binds negatively charged heparin; its positive charge explains reversal.
- Enoxaparin: within 8h, 1mg protamine/mg enoxaparin (≈100 anti-Xa units); >8h: 0.5mg/mg. After 12h, it may be unnecessary; discuss persistent bleeding/accumulation with haematology.
- Maximum 50mg/dose, IV over 10 minutes. Rapid administration risks hypotension, bradycardia and anaphylaxis; fish allergy/vasectomy increase allergy risk.
- Enoxaparin anti-Xa reversal is incomplete (maximum about 60%); idarucizumab does not reverse heparins.
- UFH: stop it. 1mg protamine/100 units, reducing with elapsed time after IV bolus: 0.5–0.75mg/100 units at 30–60 minutes. Confirm dose/route/timing with haematology/pharmacy.
- Recheck APTT after 5–15 minutes for UFH reversal. Excess protamine can worsen bleeding.
Key point
For enoxaparin within 8 hours, use protamine sulphate 1mg per 100 anti-Xa units (≈1mg per 1mg enoxaparin), maximum 50mg IV slowly — protamine causes incomplete anti-Xa reversal (maximum about 60%) and must be given slowly to avoid anaphylaxis.
Question 5 · Major Haemorrhage Protocol
Correct answer: Activate MHP early — request red cells and FFP in local emergency packs, platelets as indicated; call the senior team and guide further components by serial results
Why
Activate MHP early for life-threatening ongoing bleeding; do not wait for a fixed transfusion count.
- Initial packs: red cells and FFP, with platelets according to the local pack sequence and clinical need. For example, a published UK trauma protocol uses 4 units red cells + 4 units FFP first, then adds 1 adult therapeutic dose of platelets in the next pack; platelets may be needed earlier. This illustrates local variation, not a universal GI-bleed prescription.
- While results are unavailable: for continuing major bleeding, give at least 1 unit FFP per 2 units red cells. A universal 1:1:1 rule is inappropriate.
- Ongoing treatment: repeat coagulation tests every 30–60 minutes; guide further components by results, using ROTEM/TEG where available. In this non-obstetric case, give cryoprecipitate if fibrinogen <1.5g/L and maintain platelets >50 × 10⁹/L.
- Escalate actively: call the senior clinician, bleeding-control team, anaesthetics and haematology; confirm the alert reached them and blood bank. Continue resuscitation and urgent bleeding control.
Key point
Activate MHP early: request red cells + FFP, with platelets per local pack/clinical need, and call the senior team. Move from empirical packs to serial-result-guided replacement.
Question 6 · Restarting Anticoagulation
Correct answer: Restart anticoagulation after a multidisciplinary discussion; typically 7–14 days after haemostasis is achieved, balancing thrombotic vs haemorrhagic risk
Why
The decision to restart anticoagulation after major haemorrhage requires multidisciplinary discussion (haematology, gastroenterology, cardiology, and the patient), carefully balancing thrombotic risk (stroke, systemic embolism, DVT/PE) against re-bleeding risk. For AF: a CHA₂DS₂-VASc score of 5 confers approximately 6.7% annual stroke risk — high enough that most guidelines support restarting anticoagulation. General timing: 7–14 days after haemostasis is confirmed for GI bleeding (after successful endoscopic haemostasis). For intracranial haemorrhage, decisions are more complex — often 4–8 weeks minimum, sometimes never if risk/benefit unfavourable. Consider switching to a DOAC (if not already) as DOACs have lower intracranial haemorrhage rates than warfarin. Use an HAS-BLED score to quantify bleeding risk. Always involve the patient in the shared decision-making process.
Key point
Restart anticoagulation after major bleeding through MDT shared decision-making — typically 7–14 days after haemostasis for GI bleeds; weigh CHA₂DS₂-VASc (thrombotic) against HAS-BLED (bleeding) scores.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.